Vibegron Market
The market for Vibegron was estimated at $1.6 billion in 2024; it is anticipated to increase to $3.2 billion by 2030, with projections indicating growth to around $5.8 billion by 2035.
Global Vibegron Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2025 - 2034
The Vibegron industry revenue is expected to be around $1.8 billion in 2025 and expected to showcase growth with 12.4% CAGR between 2025 and 2034. The rapid growth rate clearly demonstrates Vibegrons rising importance in the market due to its effectiveness and strong demand across various medical fields. One of the reasons behind Vibegrons increasing market influence is its innovative approach in tackling challenges associated with overactive bladder syndrome (OAB). These progressions have resulted in enhancements in patient results which have subsequently boosted its recognition and utilization, among both healthcare providers and patients. The continuous clinical trials and research partnerships along with the creation of dosage forms have kept this product valuable, in the pharmaceutical market.
A medication called Vibegron falls under the category of beta 3 agonists and is commonly prescribed for treating symptoms associated with overactive bladder (OAB) like sudden urgency to urinate and frequent urination as well as incontinence issues. Its focused approach in addressing needs has made it a popular choice, in the market.
Market Key Insights
- The Vibegron market is projected to grow from $1.6 billion in 2024 to $5.1 billion in 2034. This represents a CAGR of 12.4%, reflecting rising demand across Overactive Bladder (OAB) Management, Urinary Incontinence Treatment and Urinary Frequency Regulation.
- Urovant Sciences, GlaxoSmithKline, Astellas Pharma are among the leading players in this market, shaping its competitive landscape.
- U.S. and UK are the top markets within the Vibegron market and are expected to observe the growth CAGR of 11.2% to 14.9% between 2024 and 2030.
- Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.7% to 13.0%.
- Transition like Shift Towards Personalized Medicine is expected to add $161 million to the Vibegron market growth by 2030.
- The Vibegron market is set to add $3.5 billion between 2024 and 2034, with manufacturer targeting Middle-Aged Population & Young Adults End-User projected to gain a larger market share.
- With Increasing prevalence of urinary disorders, and Aging population, Vibegron market to expand 222% between 2024 and 2034.
